Update on fracture risk assessment in osteoporosis.
| Autor: | McCloskey E; Division of Clinical Medicine, School of Medicine and Population Health.; Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK., Tan ATH; Fast and Chronic Programmes, Alexandra Hospital, Queenstown.; Division of Endocrinology, Department of Medicine, National University Health System, Singapore, Singapore., Schini M; Division of Clinical Medicine, School of Medicine and Population Health.; Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current opinion in endocrinology, diabetes, and obesity [Curr Opin Endocrinol Diabetes Obes] 2024 Aug 01; Vol. 31 (4), pp. 141-148. Date of Electronic Publication: 2024 May 29. |
| DOI: | 10.1097/MED.0000000000000871 |
| Abstrakt: | Purpose of Review: The assessment of fracture risk is playing an ever-increasing role in osteoporosis clinical management and informing international guidelines for osteoporosis. FRAX, a fracture risk calculator that provides individualized 10-year probabilities of hip and major osteoporotic fracture, has been widely used since 2008. In this review, we recap the development and limitations of intervention thresholds and the role of absolute fracture risk. Recent Findings: There is an increasing awareness of disparities and inequities in the setting of intervention thresholds in osteoporosis. The limitations of the simple use of prior fracture or the DXA-derived BMD T -score threshold are increasingly being discussed; one solution is to use fracture risk or probabilities in the setting of such thresholds. This approach also permits more objective assessment of high and very high fracture risk to enable physicians to make choices not just about the need to treat but what agents to use in individual patients. Summary: Like all clinical tools, FRAX has limitations that need to be considered, but the use of fracture risk in deciding who to treat, when to treat and what agent to use is a mechanism to target treatment equitably to those at an increased risk of fracture. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|